Pfizer says Phase 3 study of their COVID-19 vaccine candidate met "all primary efficacy endpoints". During its early analysis, vaccine had shown 90 per cent efficacy but final analysis involving 170 confirmed cases of COVID-19 showed 95 per cent efficacy. <br /> <br />Pfizer says Phase 3 study of their COVID-19 vaccine candidate met "all primary efficacy endpoints". During its early analysis, vaccine had shown 90 per cent efficacy but final analysis involving 170 confirmed cases of COVID-19 showed 95 per cent efficacy. <br /> <br />#PfizerInc #CoronavirusVaccine #OneindiaHindi
